logo
What Is Gua Sha and What Is it Used For?

What Is Gua Sha and What Is it Used For?

Health Line2 days ago
Gua sha is a traditional Chinese medicine technique that involves scraping your skin with a smooth-edged tool to improve circulation.
Gua sha, also known as scraping therapy, is generally performed on the back, buttocks, arms, and legs. A gentle version of it is used on the face and neck.
The practice is believed to release stagnant energy, called chi or qi, which practitioners believe may be responsible for inflammation in the body. This may support both improved blood flow and lymphatic drainage, a process by which the body maintains its fluid levels and removes cellular debris and harmful substances.
You can use gua sha massage on your own or have a licensed acupuncturist perform it.
Keep reading to learn how to use gua sha massage and the potential benefits and risks.
Gua sha is not a substitute for medical care. Readers should consult healthcare providers before trying, especially if they have medical conditions. Expand contraindications to include pregnancy, active skin conditions (eczema, psoriasis, rosacea), recent cosmetic procedures (Botox/fillers), and sunburned skin.
How to perform gua sha massage
Gua sha massage requires using a smooth-edged tool. Gua sha tools can vary in size and shape depending on the area of the body they're intended for. Tools for the face are usually smaller and handheld, while tools for the body can sometimes be larger.
You can usually find a gua sha tool online. You can find facial gua sha tools at some beauty retailers.
To perform gua sha:
Before performing gua sha massage, wash your tool with soap and warm water.
Then, apply oil or serum to the area you want to work on. This helps the tool glide across the skin.
Finally, scrape or sweep the tool upward and outward across your skin at a 15- to 30-degree angle. If you're trying gua sha for the first time, avoid applying excessive pressure until you know how your body reacts.
The amount of pressure you use when scraping the tool typically varies depending on where you are applying it. The pressure should be gentle enough for comfort but firm enough to create slight tension.
When used on the body, the gua sha tool is scraped in long strokes across the skin and can leave petechiae, tiny red or purple spots caused by broken capillaries just beneath the skin's surface. Mild bruises are also possible.
On the face, the tool should be gently swept upward and outward across the face with light pressure. It should not be enough pressure to leave petechiae. You can also use a jade roller on your face.
Licensed acupuncturists can use gua sha on different areas of the body to relieve inflammation and pain. They may determine where to use gua sha based on where you're experiencing symptoms and on acupressure points. These specific points on the body are believed to stimulate qi in Chinese traditional medicine. They correspond to specific ailments, like headaches or anxiety.
What material works best for gua sha massage?
Gua sha massage tools are often made from natural materials like polished jade or rose quartz or plastic. You can choose whichever material you prefer, based on feel and aesthetics, but common materials include:
Jade: Denser, smoother, and cooler, with benefits for working out tight muscles
Rose quartz: Softer, more porous, which may provide a lighter massage
Natural horn: Durable and stronger
Stainless steel or metal: Durable, stronger, and easier to clean
Bian stone: Durable, stronger, and able to be heated
Wood: Softest and most porous
Plastic: Inexpensive and softer
What are the potential health benefits of gua sha?
Gua sha may improve blood flow in the areas where it's applied.
Benefits may include:
improving circulation
reducing inflammation
relieving pain sensations elsewhere in the body
relaxation
A 2024 randomized controlled trial in people with Parkinson's disease suggests that gua sha may improve pain severity, motor function, affective disorder, and sleep quality.
Researchers also found the participants who underwent gua sha had increased blood levels of a hormone precursor to serotonin (5-HT), which is involved in regulating mood, and a protein (IL-10) involved in anti-inflammatory processes in the body. These participants also had reduced levels of a protein (IL-8) responsible for promoting inflammation in the body.
According to a 2023 non-randomized control trial, gua sha may also have benefits for pain and breast engorgement due to breastfeeding. Participants performed gua sha on their engorged breasts for 30 minute sessions that involved scraping each site three times for 2 minutes each over a gua sha supportive bra with arrows directing them on each scraping pattern.
A 2011 study with 48 participants compared the effects of gua sha with thermal heat pads on adults with chronic neck pain. One group received gua sha, and the control group received heat therapy. Researchers found that neck pain severity and mobility after one week were significantly better in the gua sha group compared to the control group.
A small 2017 study with 12 participants compared the effects of gua sha with hydrocollator (moist heat) packs on older adults with chronic lower back pain. One group received gua sha, and the control group received heat therapy.
Although both methods decreased pain and improved flexion, extension, and bending movement of the lower back, researchers concluded that gua sha may have a longer-lasting anti-inflammatory effect. At the one-week follow-up, more people who received gua sha experienced pain relief and improved mobility than in the control group.
More research is still needed to further evaluate these potential benefits with larger studies.
Does gua sha have side effects?
Gua sha is generally considered safe. It's not supposed to be painful, but the procedure may temporarily change the appearance of your skin.
Gua sha it involves rubbing or scraping the skin with a massage tool so that tiny blood vessels known as capillaries near the surface of your skin burst. This is believed to support blood flow.
This can result in petechiae and minor bleeding. These marks usually disappear within a couple of days and should not be painful. Some people also experience temporary indentation of the skin or mild bruising.
Cleaning the tool after each use can help reduce the risk of infection if the skin tears or bleeds. Avoid using the tool on open wounds and other areas of the skin that are irritated.
If you have a chronic health condition, take blood thinners, have a blood clotting disorder, or are taking medication that affects your blood cell production (such as chemotherapy) consult with a healthcare professional before use.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

An Inventor Is Injecting Bleach Into Cancerous Tumors—and Wants to Bring the Treatment to the US
An Inventor Is Injecting Bleach Into Cancerous Tumors—and Wants to Bring the Treatment to the US

WIRED

time6 hours ago

  • WIRED

An Inventor Is Injecting Bleach Into Cancerous Tumors—and Wants to Bring the Treatment to the US

Xuewu Liu, a Chinese inventor who has no medical training or credentials of any kind, is charging cancer patients $20,000 for access to an AI-driven but entirely unproven treatment that includes injecting a highly concentrated dose of chlorine dioxide, a toxic bleach solution, directly into cancerous tumors. One patient tells WIRED her tumor has grown faster since the procedure and that she suspects it may have caused her cancer to spread—a claim Liu disputes—while experts allege his marketing of the treatment has likely put him on the wrong side of US regulations. Nonetheless, while Liu currently only offers the treatment informally in China and at a German clinic, he is now working with a Texas-based former pharmaceutical executive to bring his treatment to America. They believe that the appointment of Robert F. Kennedy Jr. as health secretary will help 'open doors' to get the untested treatment—in which at least one clinic in California appears to have interest—approved in the US. Kennedy's Make America Healthy Again (MAHA) movement is embracing alternative medicines and the idea of giving patients the freedom to try unproven treatments. While the health secretary did not respond to a request for comment about Liu's treatment, he did mention chlorine dioxide when questioned about President Donald Trump's Operation Warp Speed during his Senate confirmation hearing in February, and the Food and Drug Administration recently removed a warning about substance from its website. The agency says the removal was part of a routine process of archiving old pages on its site, but it has had the effect of emboldening the bleacher community. 'Without the FDA's heavy-handed warnings, it's likely my therapy would have been accepted for trials years earlier, with institutional partnerships and investor support,' Liu tells WIRED. He says he wrote to Kennedy earlier this year urging him to conduct more research on chlorine dioxide. 'This quiet removal won't immediately change everything, but it opens a door. If mainstream media reports on this shift, I believe it will unlock a new wave of serious [chlorine dioxide] research.' For decades, pseudoscience grifters have peddled chlorine dioxide solutions—sold under a variety of names, such as Miracle Mineral Solution—and despite warnings and prosecutions, have continued to claim the toxic substance is a 'cure' for everything from HIV to Covid-19 to autism. There is no credible evidence to back up any of these claims, which critics have long labeled as nothing more than a grift. The treatments typically involve drinking liquid chlorine dioxide on a regular basis, using solutions with concentrations of chlorine dioxide of around 3,000 parts per million (ppm), which is diluted further in water. Liu's treatment, however, involves a much higher concentration of chlorine dioxide—injections of several milliliters of 20,000ppm—and, rather than drinking it, patients have it injected directly into their tumors. Liu claims he has injected himself with the solution over 50 times and suffered no side effects. 'This personal data point encouraged me to continue research,' he says.

What Factors Influence a Patient's Success on GLP-1s?
What Factors Influence a Patient's Success on GLP-1s?

Medscape

time8 hours ago

  • Medscape

What Factors Influence a Patient's Success on GLP-1s?

Longer treatment duration, not having diabetes, and using semaglutide were among the factors associated with better weight reduction over 12 months among patients taking GLP-1 receptor agonists (RA), a cohort study suggested. 'Treatment responses differ among patients receiving GLP-1 RAs, and the weight fluctuations and associated factors following [their] use have not been adequately characterized,' Linong Ji, MD, of Peking University People's Hospital in Beijing, China, told Medscape Medical News . The findings, published online in Diabetes, Obesity and Metabolism , 'may provide novel insights into weight fluctuations after GLP-1 RA treatment in a real-world setting,' he said, potentially advancing the development of individualized strategies for patients. 'Corroborates Other Studies' Researchers conducted a real-world, single-center, retrospective study of 679 patients with overweight or obesity who initiated GLP-1 RA treatment between November 2022 and October 2024. At baseline, participants had a mean age of 37 years, and 31% were men. The mean BMI was 33.4, and 21% were diagnosed with diabetes. The GLP-1 RAs used in the study included semaglutide (Ozempic), liraglutide (Victoza), lixisenatide (Lyxumia), beinaglutide (Yishengtai), exenatide (Bydureon), dulaglutide (Trulicity), and PEG-loxenatide (Fulaimei). All were available for participants with both type 2 diabetes (T2D) and overweight/obesity. For participants with overweight/obesity but without T2D, only Ozempic or Victoza were routinely prescribed, with off-label documentation and informed consent. Weight measurements were collected during in-person clinic visits, and weight fluctuation curves were stratified into three phenotypes — Successful Weight Reduction, Remaining Stable, and Weight Regain. Subsequently, the association between potential influencing factors and weight fluctuations was estimated by univariate and multivariate logistic regression. Subgroup analyses were performed in participants with obesity, prediabetes, and in those using liraglutide or semaglutide. Researchers found significant differences in the duration of GLP-1 RA treatment across groups at the 3-, 6-, and 12-month follow-ups. The Successful Weight Reduction group had a significantly longer duration of GLP-1 RA treatment than the Remaining Stable group and a longer duration at both the 6- and 12-month follow-ups than the Weight Regain group. Diabetes status also showed group differences. At both the 3- and 6-month follow-ups, the proportion of patients with T2D in the Successful Weight Reduction group was lower than in the Remaining Stable group. Types of GLP-1 RAs varied between groups, and at the 3- and 6-month follow-ups, the Successful Weight Reduction group was more likely to have initiated treatment with semaglutide than the Remaining Stable group. Patients with a longer duration of GLP-1 RA treatment (odds ratio [OR], 1.014) and higher Homeostasis Model Assessment of Beta-Cell Function levels (OR, 4.912) were more likely to achieve successful weight reduction at the 12-month follow-up. Nondiabetic status (OR, 2.176) and using semaglutide (OR, 2.138) were associated with successful weight reduction at the 6-month follow-up. In addition, a higher percentage of body fat in both men (OR, 3.990) and women (OR, 2.266) was associated with successful weight reduction. The weight regain group had a higher baseline estimated glomerular filtration rate than the Successful Weight Reduction group and the Remaining Stable group at 3-month follow-up, especially among participants with prediabetes. Ji said this finding surprised him. Patients with obesity often exhibit a state of renal hyperfiltration, characterized by elevated renal plasma flow and glomerular filtration rate, which can be reversed by weight reduction. The finding suggests that patients with renal hyperfiltration might be less likely to experience durable weight reduction, Ji said. 'However, few studies have revealed similar observations. Therefore, further validations and investigations are still needed for this finding.' Furthermore, the team found a positive nonlinear association of serum creatinine with successful weight reduction at 12 months — a finding that will also require additional investigations to examine the mechanism underlying the association. Overall, Ji concluded that while longer duration of GLP-1 RA treatment using semaglutide, nondiabetic status, and higher percentage of body fat might be associated with better weight reduction, 'basal metabolic rate, skeletal muscle mass, muscle mass of the abdomen and limbs, and serum creatinine were nonlinearly associated with the probability of successful weight reduction.' Randy Seeley, MD, Henry King Ransom Endowed Professor of Surgery, Internal Medicine, and Nutritional Sciences at the University of Michigan School of Medicine, Ann Arbor, Michigan, and director of the National Institutes of Health-funded Michigan Nutrition Obesity Research Center, told Medscape Medical News , 'The main results of the study agree with what the field has already seen. Although it is a relatively small study, it corroborates other larger studies,' said Seeley, who was not involved in the study. This work was supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project. Ji reported receiving fees for lecture presentations and for consulting from AstraZeneca, Merck, Metabasis, MSD, Novartis, Eli Lilly and Company, Roche, Sanofi-Aventis, and Takeda. Seeley reported that his lab has worked with both Novo and Lilly (and others trying to enter the space), and he has also served as a paid consultant for both of those companies (and others trying to enter the space).

DLBCL: FDA Rejects BLA for Second-Line Glofitamab Combo
DLBCL: FDA Rejects BLA for Second-Line Glofitamab Combo

Medscape

time9 hours ago

  • Medscape

DLBCL: FDA Rejects BLA for Second-Line Glofitamab Combo

The FDA rejected a supplemental Biologics License Application (sBLA) for glofitamab-gxbm (Columvi, Genentech) in combination with gemcitabine and oxaliplatin for the second-line treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients who are not candidates for autologous stem cell transplant. A complete response letter from the FDA stated that Genentech's phase 3 STARGLO trial did not provide sufficient evidence to support the proposed second-line DLBCL indication for the T cell engaging bispecific antibody in the US, according to a Genentech statement. However, a conditional FDA approval in the third-line or greater setting remains in place. FDA's decision regarding second-line glofitamab aligns with an advisory committee vote in May, which cited a lack of US patient representation in the trial. The Oncologic Drugs Advisory Committee (ODAC) voted 8-1 against recommending approval, as reported by Medscape Medical News . The FDA asked for ODAC review over concerns that nearly half of the STARGLO participants were from Korea, Taiwan, and China, with most of the remaining participants coming from Europe and Australia. Only 25 US patients were included. Outcomes among Asian vs non-Asian patients differed, with a strong trend toward worse overall survival (OS), rates in White patients and patients from Europe and the US, despite a strong overall 0.59 hazard ratio for OS. Similar trends were observed for progression-free survival and complete response rates. At the time, the FDA said the low US enrollment 'limits the agency's ability to assess the applicability of the study results to a US patient population,' and cited additional concerns regarding comparator drugs used in the trial, according to meeting documents. 'While we are disappointed with this outcome, we remain confident in the data supporting the value of Columvi for US patients who have relapsed following initial treatment, and its key role as monotherapy in the third-line setting,' Genentech's Chief Medical Officer and head of Global Product Developments, Levi Garraway, MD, PhD, said in the company statement regarding the sBLA rejection. 'We are committed to bringing Columvi to more people living with lymphoma and are actively exploring its potential in additional treatment settings, including as frontline therapy.' 'For patients with this aggressive form of lymphoma, effective treatment after relapse is paramount,' added Jeremy Abramson, MD, the principle STARGLO investigator and director of the Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center, Boston. Abramson stressed that in the STARGLO trial, the glofitamab combination therapy improved OS, which 'could have a positive impact for patients earlier in their treatment journey.' The regimen is currently approved for this indication in more than 35 countries. It is approved in more than 60 countries for third-line or greater treatment of DLBCL, including in the US where the FDA granted accelerated approval in 2023. STARGLO was also intended as a post-marketing confirmatory study to support conversion of the accelerated approval to full approval, Genentech noted. Results were published in 2024 in The Lancet, and 2-year follow-up data showing sustained overall improvements in the primary and secondary endpoints were presented at 2025 American Society of Clinical Oncology Meeting. Genentech said the regimen is currently being investigated in combination with other agents as a first-line treatment for DLBCL in the phase 3 SKYGLO study.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store